Zentalis Pharmaceuticals (ZNTL) Cash from Operations (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Cash from Operations of 32956000.0 for Q1 2026, down 0.98% year-over-year from 33282337.42 in Q1 2025, and down 6.52% quarter-over-quarter from 30940000.0 in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Cash from Operations (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Cash from Operations history runs 8 years deep, the most recent figure standing at 32956000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 0.98% year-over-year to 32956000.0; the TTM figure through Mar 2026 stood at 125567000.0 (up 17.13% YoY), while the FY2025 annual figure was 125247000.0, up 26.7% from the prior year.
- Cash from Operations for Q1 2026 stood at 32956000.0, down from 30940000.0 in the prior quarter.
- The five-year high for Cash from Operations was 26963000.0 in Q3 2025, with the low at 79275000.0 in Q2 2023.
- The 5-year median for Cash from Operations is 38665000.0 (2023), against an average of 41213882.35.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations sank 84.24% in 2023, then surged 55.67% in 2024.
- Zentalis Pharmaceuticals' Cash from Operations stood at 37329000.0 in 2022, then declined by 8.76% to 40599000.0 in 2023, then advanced by 2.21% to 39702000.0 in 2024, then rose by 22.07% to 30940000.0 in 2025, then retreated by 6.52% to 32956000.0 in 2026.
- Business Quant data shows ZNTL's Cash from Operations at 32956000.0 in Q1 2026, 30940000.0 in Q4 2025, and 26963000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | -37.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.24 Mn |
| Jun 30, 2026 | -37.24 Mn |
| Mar 31, 2026 | -32.96 Mn |
| Mar 31, 2026 | -32.96 Mn |
| Dec 31, 2025 | -30.94 Mn |
| Dec 31, 2025 | -30.94 Mn |
| Sep 30, 2025 | -26.96 Mn |
| Sep 30, 2025 | -26.96 Mn |
| Jun 30, 2025 | -34.71 Mn |
| Jun 30, 2025 | -34.71 Mn |
| Mar 31, 2025 | -32.64 Mn |
| Mar 31, 2025 | -32.64 Mn |
| Dec 31, 2024 | -39.70 Mn |
| Dec 31, 2024 | -39.70 Mn |
| Sep 30, 2024 | -44.05 Mn |
| Sep 30, 2024 | -44.05 Mn |
| Jun 30, 2024 | -35.14 Mn |
| Jun 30, 2024 | -35.14 Mn |
| Mar 31, 2024 | -51.97 Mn |
| Mar 31, 2024 | -51.97 Mn |